Postsurgery serum thyroglobulin disappearance kinetic in patients with differentiated thyroid carcinoma

Head and Neck

Volumn 32, Issue 5, 2010, Pages 568-571

  Giovanella, Luca ^a   Ceriani, Luca ^a   Maffioli, Marco ^b  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b OSPEDALE DI CIRCOLO   (Italy)

Author keywords

Differentiated thyroid carcinoma; Half life; Kinetic; Thyroglobulin; Thyroidectomy

Indexed keywords

THYROGLOBULIN ANTIBODY;

ADULT; AGED; ANTIBODY SCREENING; ARTICLE; COMPARTMENT MODEL; FEMALE; HALF LIFE TIME; HUMAN; IMMUNOASSAY; KINETICS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; PRIORITY JOURNAL; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROIDECTOMY;

ADOLESCENT; ADULT; AGED; CARCINOMA; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; YOUNG ADULT;

EID: 77951577050     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21214     Document Type: Article

References (14)

1. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433-1441.
2. Spencer CA. Serum thyroglobulin measurements: clinical utility and technical limitations in the management of patients with differentiated thyroid carcinomas. Endocr Pract 2000;6:481-484.
3. Feldt-Rasmussen U, Petersen PH, Nielsen H, Date J, Madsen CM. Thyroglobulin of varying molecular sizes with different disappearance rates in plasma following subtotal thyroidectomy. Clin Endocrinol (Oxf) 1978;9:205-214.
4. Izumi M, Kubo I, Taura M, et al. Kinetic study of immunoreactive human thyroglobulin. J Clin Endocrinol Metab 1986;62:410-412.
5. Hocevar M, Auersperg M, Stanovnik L. The dynamics of serum thyroglobulin elimination from the body after thyroid surgery. Eur J Surg Oncol 1997;23:208-210.
6. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S. LoPresti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 2005;90:5566-5575.
7. Giovanella L. Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management. Clin Chem Lab Med 2008;46:1067-1073.
8. Bidart JM, Thuillier F, Augereau C, et al. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin Chem 1999;45:1695-1707.
9. Giovanella L, Ceriani L, Ghelfo A, et al. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant thyrotropin-stimulated assay and imaging procedures. Clin Chem Lab Med 2006;44:648-652.
10. Preissner CM, O'Kane DJ, Singh RJ, Morris JC, Grebe SK. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab 2003;88:3069-3074.
11. Stamey TA. Lower limits of detection, biological detection limits, functional sensitivity, or residual cancer detection limit? Sensitivity reports on prostate-specific antigen assays mislead clinicians. Clin Chem 1996;42(6 Pt 1):849-852.
12. Gion M, Mione R, Barioli P, Dittadi R. Dynamic use of tumor markers, rationale - clinical applications and pitfalls. Anticancer Res 1996;16:2279-2284.
13. Kiang DT, Greenberg LJ, Kennedy BJ. Tumor marker kinetics in the monitoring of breast cancer. Cancer 1990;65:193-199.
14. Hay ID. Management of patients with low-risk papillary thyroid carcinoma. Endocr Pract 2007;13:521-533.